Loading
Busque productos, empresas, pruebas y guías: pase de la consulta a la solicitud de cotización en un solo lugar.
Pruebas
A proprietary chemiluminescent microparticle immunoassay (CMIA) used for the qualitative detection of IgM antibodies to SARS-CoV-2 in human serum and plasma on the Abbott Alinity i system. The presence of IgM antibodies may be associated with recent infection or may assist with the evaluation of disease course.
Pruebas
A chemiluminescent microparticle immunoassay (CMIA) used for the qualitative detection of IgM antibodies to SARS-CoV-2 in human serum and plasma on the Abbott ARCHITECT i system. The presence of IgM antibodies may be associated with recent infection or may assist with the evaluation of disease course.
Pruebas
The determination of the antidrug binding IgG and/or IgM antibody in a biospecimen.
Pruebas
The determination of the amount of Borrelia burgdorferi IgM antibody present in a sample.
Pruebas
The determination of the amount of Chlamydia pneumoniae IgM antibody present in a sample.
Pruebas
The determination of the amount of Chlamydia trachomatis IgM antibody present in a sample.
Pruebas
The determination of the cross-reactive antidrug binding IgG and/or IgM antibody in a biospecimen.
Pruebas
The determination of the number of Ebola virus-specific IgM antibody secreting cells in a biological sample.
Pruebas
A proprietary enzyme-linked immunosorbent assay for semi-quantitative detection of IgM antibodies against SARS-CoV-2 using a modified nucleocapsid protein (NCP) containing only diagnostically relevant epitopes.
Pruebas
The determination of the amount of Hepatitis A virus antibody IgM present in a sample.
Pruebas
The determination of the amount of hepatitis D virus IgM antibody in a biological specimen.
Pruebas
The determination of the amount of Herpes Simplex virus 1/2 IgM antibody present in a sample.
